Insulin Glulisine
Title: Insulin Glulisine
CAS Registry Number: 207748-29-6
CAS Name: 3B-L-Lysine-29B-L-glutamic acid-insulin (human)
Additional Names: [Lys(B3),Glu(B29)]-insulin (human)
Manufacturers' Codes: HMR-1964
Trademarks: Apidra (Sanofi-Aventis)
Molecular Formula: C258H384N64O78S6
Molecular Weight: 5822.58
Percent Composition: C 53.22%, H 6.65%, N 15.40%, O 21.43%, S 3.30%
Literature References: Rapid-acting insulin analog produced in E. coli by recombinant DNA technology. Identical to human insulin except for 2 amino acid substitutions. Prepn: J. Ertl et al., EP 885961 (1998 to Hoechst Marion Roussel); eidem, US 6221633 (2001 to Aventis). Evaluation of mitogenic potential: I. Rakatzi et al., Diabetes 52, 2227 (2003); of b-cell protective effect: idem et al., Biochem. Biophys. Res. Commun. 310, 852 (2003). Clinical trial in type 2 diabetes: G. Dailey et al., Diabetes Care 27, 2363 (2004). Review: S. K. Garg et al., Expert Opin. Pharmacother. 6, 643-651 (2005).
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic; Hormones/Analogs.

Others monographs:
Beryllium Acetylacetonatep-AminoazobenzeneWheat Germ OilTriclopyr
NidulinChloroarsenolNiaprazineSenecionine
PeriplocymarinIndium Gallium Aluminum PhosphideD-Gulonic AcidSulfinalol
PosaconazolePeanut OilCoproergostaneCassella's Acid
©2016 DrugLead US FDA&EMEA